Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

7.520 -0.670 (-8.18%)

Streaming Delayed Price Updated: 3:02 PM EDT, Apr 24, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	13,009,092
Open	8.160
Bid (Size)	7.520 (1,700)
Ask (Size)	7.530 (4,600)
Prev. Close	8.190
Today's Range	7.520 - 8.280
52wk Range	1.830 - 12.43
Shares Outstanding	391,156,513
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit

Today 12:40 EDT

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit

Today 12:40 EDT

Did you buy IBRX securities between January 19, 2026, and March 24, 2026?

Via TheNewswire.com

Performance

YTD	+272.3%	+272.3%
1 Month	+1.4%	+1.4%
3 Month	+2.5%	+2.5%
6 Month	+214.6%	+214.6%
1 Year	+179.6%	+179.6%

More News

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Today 10:20 EDT

From Schall Law

Via GlobeNewswire

ImmunityBio, Inc. (IBRX) Securities Fraud Class Action Lawsuit Filed; May 26, 2026, Lead Plaintiff Deadline

April 23, 2026

Via NewMediaWire

ImmunityBio, Inc. (IBRX) Securities Fraud Class Action Lawsuit Filed; May 26, 2026, Lead Plaintiff Deadline

April 23, 2026

Via TheNewswire.com

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

April 23, 2026

From SkyMedia, LLC

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Securities Class Action Lawsuit Filed Against ImmunityBio, Inc. (IBRX)

April 23, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

ImmunityBio, Inc. (IBRX) Class Action Lawsuit: Investors Face May 26, 2026, Deadline

April 22, 2026

Via NewMediaWire

ImmunityBio, Inc. (IBRX) Class Action Lawsuit: Investors Face May 26, 2026, Deadline

April 22, 2026

Via TheNewswire.com

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

April 21, 2026

From Kahn Swick & Foti, LLC

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX

April 21, 2026

From Pomerantz LLP

Via GlobeNewswire

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 21, 2026

From Schall Law

Via GlobeNewswire

ImmunityBio Stock Rises As ANKTIVA Launches in Saudi Arabia ↗

April 21, 2026

Via Benzinga

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)

April 21, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

Deadline Approaching for Investors of ImmunityBio, Inc. (NASDAQ: IBRX) - Contact Kaplan Fox Before May 26, 2026

April 20, 2026

Via NewMediaWire

Deadline Approaching for Investors of ImmunityBio, Inc. (NASDAQ: IBRX) - Contact Kaplan Fox Before May 26, 2026

April 20, 2026

Via TheNewswire.com

ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.

April 20, 2026

From Lowey Dannenberg, P.C.

Via GlobeNewswire

ImmunityBio, Inc. (IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit

April 19, 2026

Via NewMediaWire

ImmunityBio, Inc. (IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit

April 19, 2026

Via TheNewswire.com

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

April 19, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit

April 18, 2026

Via NewMediaWire

ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit

April 18, 2026

Via TheNewswire.com

IMMUNITYBIO DEADLINE FOR LEADERSHIP is May 26, 2026 in a Securities Fraud Lawsuit - Investors Encouraged to Contact Kaplan Fox

April 18, 2026

Via NewMediaWire

IMMUNITYBIO DEADLINE FOR LEADERSHIP is May 26, 2026 in a Securities Fraud Lawsuit - Investors Encouraged to Contact Kaplan Fox

April 18, 2026

Via TheNewswire.com

ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.

April 17, 2026

From Lowey Dannenberg, P.C.

Via GlobeNewswire

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?

Yes, ImmunityBio, Inc. - Common Stock is publicly traded.

What exchange does ImmunityBio, Inc. - Common Stock trade on?

ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ImmunityBio, Inc. - Common Stock?

The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market

What is the current price of ImmunityBio, Inc. - Common Stock?

The current price of ImmunityBio, Inc. - Common Stock is 7.520

When was ImmunityBio, Inc. - Common Stock last traded?

The last trade of ImmunityBio, Inc. - Common Stock was at 04/24/26 03:02 PM ET

What is the market capitalization of ImmunityBio, Inc. - Common Stock?

The market capitalization of ImmunityBio, Inc. - Common Stock is 2.94B

How many shares of ImmunityBio, Inc. - Common Stock are outstanding?

ImmunityBio, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.